WO1996038416A1 - Acide (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazin-1-yl]phenoxy}butyrique inhibiteur d'adhesion cellulaire - Google Patents

Acide (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazin-1-yl]phenoxy}butyrique inhibiteur d'adhesion cellulaire Download PDF

Info

Publication number
WO1996038416A1
WO1996038416A1 PCT/GB1996/001260 GB9601260W WO9638416A1 WO 1996038416 A1 WO1996038416 A1 WO 1996038416A1 GB 9601260 W GB9601260 W GB 9601260W WO 9638416 A1 WO9638416 A1 WO 9638416A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically
optically active
ester
active compound
amide
Prior art date
Application number
PCT/GB1996/001260
Other languages
English (en)
Inventor
Stuart Dennett Mills
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/457,538 external-priority patent/US5652242A/en
Priority claimed from GBGB9518188.9A external-priority patent/GB9518188D0/en
Priority to KR1019970700532A priority Critical patent/KR100245957B1/ko
Priority to NZ308597A priority patent/NZ308597A/en
Priority to JP8536281A priority patent/JP2885941B2/ja
Priority to BR9606409A priority patent/BR9606409A/pt
Priority to AU58272/96A priority patent/AU710105B2/en
Priority to MX9700379A priority patent/MX9700379A/es
Priority to SK130-97A priority patent/SK13097A3/sk
Priority to EP96919906A priority patent/EP0796247A1/fr
Application filed by Zeneca Limited filed Critical Zeneca Limited
Priority to AT0900596A priority patent/AT406675B/de
Priority to GB9627127A priority patent/GB2304340B/en
Priority to DE19680509T priority patent/DE19680509T1/de
Priority to CZ97269A priority patent/CZ26997A3/cs
Publication of WO1996038416A1 publication Critical patent/WO1996038416A1/fr
Priority to LU90008A priority patent/LU90008B1/fr
Priority to SE9700203A priority patent/SE510812C2/sv
Priority to DK010697A priority patent/DK10697A/da
Priority to FI970393A priority patent/FI970393A/fi
Priority to NO970437A priority patent/NO307460B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention relates to the novel optically active compound (-)-(3R)-3-methyl-4- ⁇ 4- [4-(4-pyridyl)piperazin- 1 -yl]phenoxy ⁇ butyric acid, [hereinafter (-)-(3R)] and pharmaceutically-acceptable salts, esters, amides or solvates thereof.
  • the invention also relates to processes for the preparation of the optically active compound, pharmaceutical compositions containing it and its use to inhibit cellular adhesion, for example platelet aggregation.
  • Organic compounds can exist in optically active forms. Such compounds possess the property of being able to rotate the plane of plane-polarised light in either a dextrorotary [prefix (+)] or laevorotary [prefix (-)] manner.
  • an optically active compound possesses an asymmetric or chiral atom such as a tetrahedral carbon atom which is bonded to four different atoms or groups. The four different atoms or groups can be arranged around the asymmetric carbon atom in two ways to give two chiral compounds which are structurally related as mirror images of one another. Such compounds are termed stereoisomers or enantiomers.
  • Enantiomers have identical physical and chemical properties except that they rotate the plane of plane-polarised light by an equal amount but in opposite directions.
  • a racemic mixture is a mixture of equal amounts of a pair of enantiomers. Such a mixture does not cause rotation of the plane of plane-polarised light.
  • the stereochemical purity of an organic compound can be of importance in the fields of pharmaceutical chemistry and pharmacology.
  • Many macromolecules such as the enzymes and receptors within warm-blooded animals which are involved in the maintenance of life are built up from chiral building blocks such as the chiral amino acids.
  • the individual enantiomers which together make up a racemic mixture of a pharmacologically- active compound may interact to differing extents with a chiral macromolecule such as an enzyme or receptor.
  • the individual enantiomers may therefore possess different potencies as enzyme inhibitors or receptor antagonists.
  • the rate and extent of the absorption, distribution, metabolism and excretion observed when one enantiomer is dosed to a warm-blooded animal may differ from that observed when the mirror image form is so dosed, i.e. the enantiomers may possess different pharmacokinetic properties.
  • the stereochemical purity of an organic compound may also be of importance to the nature and extent of the side effects which may be obtained when a pharmacologically-active compound is dosed.
  • one enantiomer may be a useful compound whereas the other enantiomer may give rise to deleterious side effects or toxicity. It has, for example, been suggested that one of the enantiomers of thalidomide was a safe and effective sedative whereas the other enantiomer controlled the racemic mixture's teratogenic side effect.
  • the optically active compound of the present invention is an optical isomer of the racemic mixture (3RS)-3-methyl-4- ⁇ 4-[4-(4-pyridyl)piperazin-l-yl]-phenoxy ⁇ butyric acid [hereinafter the (3RS)-racemic mixture] which is disclosed, as the trifluoroacetic acid salt, in Example 132 of International Patent Application No. WO 94/22834 and Example 203 of International Patent Application No. WO 94/22835. It is disclosed therein that such compounds are useful in the treatment of a variety of diseases involving cell adhesion such as the formation of blood thrombi following platelet aggregation. Blood thrombi can lead to diseases such as thrombosis, stroke, thrombotic events accompanying unstable angina, myocardial infarction, atherosclerosis, thromboembolism and reocclusion during or after thrombolytic therapy.
  • the anti-platelet aggregatory effect of the compounds is stated to be based on the compounds' ability to inhibit the binding of adhesion molecules such as fibrinogen and von Willebrand Factor to glycoprotein ⁇ b/Tfla (hereinafter GPIIb/Tfla) which is held within the membrane of each platelet.
  • adhesion molecules such as fibrinogen and von Willebrand Factor to glycoprotein ⁇ b/Tfla (hereinafter GPIIb/Tfla) which is held within the membrane of each platelet.
  • Integrins are found on leucocytes and platelets and selectins are found on leucocytes and endothelial cells. Within each class of adhesion molecules there are many members.
  • the integrin family includes, for example, GP ⁇ b/LIa which binds fibrinogen, the integrin ⁇ v ⁇ 3 which binds vitronectin and the integrin a which binds fibronectin. It is believed that the more useful therapeutic platelet aggregation inhibitors will possess selectivity of inhibitory effect between classes of adhesion molecules and between family members of each class of adhesion molecules. Thus it would also be desirable to find a compound which possesses this selectivity or which possesses greater selectivity than known platelet aggregation inhibitors.
  • GPHb/Tfla antagonists there are several classes of GPHb/Tfla antagonists. For example, monoclonal antibody antagonists to GP ⁇ b/IIIa have been raised.
  • small molecules which inhibit the binding of adhesion molecules to GP ⁇ b/Tfla are also known, for example from US Patent Nos. 5,039,805 and 5,084,446, from Canadian Patent Application Nos. 2,008,161, 2,037,153 and 2,061,661, and from Alig et al, J. Med. Chem., 1992, 35, 4393.
  • the structures of these compounds are based upon the binding regions of the adhesion molecules, for example the amino acid sequence RGD (arginyl glycyl aspartate) within the structure of fibrinogen.
  • optically active compound (-)-(3R)-3-methyl-4- ⁇ 4-[4-(4-pyridyl)piperazin-J-yl]-phenoxy ⁇ butyric acid, or a pharmaceutically-acceptable salt, ester, amide or solvate thereof, substantially free of the (+)-(3S) stereoisomer.
  • the (-)-(3R) compound possesses substantially better potency as a GPIIb/IHa antagonist than the corresponding (+)-(3S) isomer (greater than 10-fold more potent).
  • the (-)-(3R) compound is a novel, potent and selective fibrinogen receptor antagonist that substantially reduces the liability or possibility of obtaining adverse effects such as excessive bleeding associated with the administration of other fibrinogen receptor antagonists such as the (3RS)-racemic mixture.
  • Use of the (-)-(3R) compound also eliminates the liability or possibility of obtaining adverse effects associated with the administration of the therapeutically less effective (+)-(3S) compound which is a constituent of the (3RS)-racemic mixture.
  • Use of the (-)-(3R) compound allows a clearer structure-activity-toxicity analysis and provides an improved therapeutic ratio. It is therefore desirable to use the (-)-(3R) compound of the present invention rather that the (3RS)-racemic mixture of Example 132 of International Patent Application No. WO 94/22834.
  • Particular pharmaceutically-acceptable salts of the (-)-(3R) compound of the invention include, for example, salts with acids affording physiologically-acceptable anions, such as salts with mineral acids, for example a hydrogen halide such as hydrogen chloride or hydrogen bromide, sulphuric acid or phosphoric acid, and salts with organic acids, for example trifluoroacetic acid.
  • Other pharmaceutically-acceptable salts include, for example, salts with inorganic bases such as alkali metal and alkaline earth metal salts e.g.
  • sodium salts, ammonium salts, and salts with organic amines and quaternary bases forming physiologically-acceptable cations such as salts with methylamine, dimethylamine, trm ethylamine, ethylenediamine, piperidine, morpholine, pyrrolidine, piperazine, ethanolamine, triethanolamine, N-methylglucamine, tetramethylammonium hydroxide and benzyltrimethylammonium hydroxide.
  • esters of the (-)-(3R) compound of the invention include, for example, ester derivatives of the carboxylic acid group in the compound of the invention, for example esters formed with alcohols such as (l-6C)alcohols (e.g. methanol, ethanol, propanol and tert-butanol), indanol, adamantol, (l-6C)alkanoyloxy- (l-4C)alcohols (e.g. pivaloyloxymethanol) and (l-4C)alkoxycarbonyl-(l-4C)alcohols (e.g. methoxycarbony lmethanol) .
  • alcohols such as (l-6C)alcohols (e.g. methanol, ethanol, propanol and tert-butanol), indanol, adamantol, (l-6C)alkanoyloxy- (l-4C)alcohols (e.g. pivaloyl
  • Particular pharmaceutically-acceptable amides of the (-)-(3R) compound of the invention include, for example, amide derivatives of the carboxylic acid group in the compound of the invention, for example amides formed with amines such as ammonia, (l-4C)alkylamines (e.g. methylamine), di-(l-4C)alkylamines (e.g. dimethylamine, N- ethyl-N-methylamine and diethylamine), (l-4C)alkoxy-(2-4C)alkylamines (e.g. 2-methoxyethylamine), phenyl-(l-4C)alkylamines (e.g. benzylamine) and amino acids (e.g.
  • amines such as ammonia, (l-4C)alkylamines (e.g. methylamine), di-(l-4C)alkylamines (e.g. dimethylamine, N- ethyl-N-methylamine and dieth
  • amides of the (-)-(3R) compound of the invention include the N-methyl-, N,N-dimethyl-, N-ethyl-N-methyl- and N,N- diethyl-butyramides.
  • Particular pharmaceutically-acceptable solvates of the (-)-(3R) compound of the invention include, for example, hydrates e.g. a hemi-hydrate, mono-hydrate, di-hydrate or tri-hydrate or an alternative quantity thereof.
  • substantially free of the (+)-(3S) stereoisomer means that there is at least 90% by weight of the (-)-(3R) isomer and 10% by weight or less of the corresponding (+)-(3S) isomer. Preferably there is at least 95% by weight of the (-)-(3R) isomer and 5% by weight or less of the (+)-(3S) isomer. More preferably there is at least 99% by weight of the (-)-(3R) isomer and 1% by weight or less of the (+)-(3S) isomer.
  • the (-)-(3R) compound of the invention may be prepared by any process known in the art for the preparation of such a compound. Suitable procedures include asymmetric synthesis involving an appropriate chiral intermediate and resolution of the (3RS)-racemic mixture. " Such procedures represent a further feature of the invention and include the following: a) Reaction of 4-[4-(4-pyridyl)piperazin- 1 -yl]phenol, or a reactive derivative thereof, with the chiral intermediate (3R)-4-hydroxy-3-methylbutyric acid or an ester thereof, or a reactive derivative thereof.
  • the reaction is conveniently performed in the presence of a strong base, such as an alkali metal hydride, for example, sodium hydride.
  • a strong base such as an alkali metal hydride, for example, sodium hydride.
  • Suitable solvents include amides, such as dimethylformamide.
  • the reaction is conveniently performed at a temperature in the range of from 0 to 100 °C.
  • Suitable esters of the chiral intermediate (3R)-4-hydroxy-3-methylbutyric acid include, for example, the methyl, ethyl, propyl and tert-butyl esters.
  • Suitable reactive derivatives thereof include, for example, (3R)-4-halogeno-3-methylbutyric acid or an ester thereof (e.g. a methyl or ethyl ester) such as the 4-chloro and 4-bromo derivatives, (3R)-4-alkanesulphonyloxy-3-methylbutyric acid or an ester thereof (e.g.
  • a methyl or ethyl ester such as the 4-methanesulphonyloxy derivative or (3R)-4-arylsulphonyloxy-3- methylbutyric acid or an ester thereof (e.g. a methyl or ethyl ester) such as the 4-(p- toluenesulphonyloxy) derivative, b) Reaction of a compound of formula I
  • values for L include halogen, such as chlorine or bromine, and cyano.
  • Examples of acid addition salts of (3R)-3-methyl-4-[4-(piperazin-l-yl)- phenoxyjbutyric acid include, for example, the hydrochlorides.
  • the reaction may conveniently be effected at a temperature in the range of from -10 to 120 °C, preferably from 10 to 100 °C.
  • Suitable solvents include, e.g. ethers such as tetrahydrofuran and dioxan, amides such as dimethylformamide, nitriles such as acetonitrile, halogenated hydrocarbons such as dichloromethane, alcohols such as ethanol and water.
  • the reaction may advantageously be performed in the presence of a base.
  • bases include tertiary amines, such as triethylamine, and alkali metal hydroxides, carbonates and bicarbonates, such as sodium or potassium hydroxide, carbonate or bicarbonate, c) Decomposition of an ester of formula II
  • R is a carboxyl protecting group
  • R may be any conventional carboxyl protecting group that may be removed without interfering with other parts of the molecule.
  • carboxyl protecting groups include (l-6C)alkyl groups (such as methyl, ethyl, propyl or t-butyl), phenyl and benzyl, the phenyl moiety in any of which may optionally bear 1 or 2 of halogeno, (l-4C)alkyl, (l-4C)alkoxy or nitro.
  • the decomposition may be carried out using any one of the conventional reagents and conditions known in the art for converting carboxylic esters into carboxylic acids.
  • the decomposition may be performed by base catalysed hydrolysis, e.g. using an alkali metal hydroxide such as lithium, potassium or sodium hydroxide, or a tertiary amine such as triethylamine in the presence of water.
  • the base catalysed hydrolysis may be performed in the presence of a solvent such as an alcohol, e.g. methanol or ethanol, or an ether such as tetrahydrofuran or dioxan.
  • the decomposition may be carried out by acid catalysed hydrolysis, e.g.
  • aqueous acetic acid or trifluoroacetic acid The temperature is conveniently in the range of from -10 to 100°C, for example from 10 to 50°C.
  • the alcohol residue is t-butyl, this may be removed by heating, e.g. at a temperature in the range of from 80 to 150°C, alone or in the presence of a suitable diluent such as diphenylether or diphenylsulphone.
  • a benzyl group may be removed by catalytic hydrogenation, e.g. by hydrogenation in the presence of palladium on carbon at a temperature in the range of from -10 to 100°C in the presence of a solvent such as an alcohol, for example methanol or ethanol.
  • the resolution of the butyric acid derivative of the (3RS)-racemic mixture may be carried out by conventional means, for example by salt formation using an optically active base followed by separation, for example by fractional crystallisation of the two salts so produced and regeneration of the separated (-)-(3R) and (+)-(3S) compounds by acidification of the separated salts.
  • the resolution of the butyric acid derivative of the (3RS)-racemic mixture may also be carried out by the conventional means of forming a diastereoisomeric pair of esters by reaction with an optically active alcohol, separation of the esters, for example by chromatography, and regeneration of the separate (-)-(3R) and (+)-(3S) compounds by hydrolysis of the separated esters.
  • An analogous route involving the preparation of a diastereoisomeric pair of amides may also be employed.
  • a pharmaceutically-acceptable salt of the (-)-(3R) compound of the invention When a pharmaceutically-acceptable salt of the (-)-(3R) compound of the invention is required, it may be obtained, for example, by reaction of said compound with a suitable acid or base using a conventional procedure. When a pharmaceutically-acceptable ester or amide of the (-)-(3R) compound of the invention is required, it may be obtained, for example, by reaction of said compound with a suitable alcohol or amine as appropriate using a conventional procedure.
  • the ability of the (-)-(3R) compound of the invention to inhibit platelet aggregation and to inhibit the binding of fibrinogen to GPIIb/TJIa may be demonstrated using the standard test procedures (a) and (b) disclosed in International Patent Application No. WO 94/22834, which test procedures are incorporated herein by way of reference.
  • ADP adenosine diphosphate
  • the (-)-(3R) compound of the invention may be used in the therapy or prevention of diseases in which cell adhesion (especially platelet aggregation) is involved, for example venous or arterial thrombosis (e.g. pulmonary embolism, stroke and thrombotic events accompanying unstable angina and transient ischaemic attack), myocardial infarction, atherosclerosis, thromboembolism and reocclusion during and after thrombolytic therapy.
  • the compounds may also be useful for the prevention of reocclusion and restenosis following percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft.
  • PTCA percutaneous transluminal coronary angioplasty
  • the compounds may be useful in the treatment of other diseases mediated by binding of adhesion molecules to GPIIb/IIIa, for example cancer.
  • a method of inhibiting platelet aggregation in a warm-blooded animal requiring such treatment which comprises administering an effective amount of the (-)-(3R) compound, or a pharmaceutically-acceptable salt, ester, amide or solvate thereof, substantially free of the (+)-(3S) stereoisomer.
  • a method of inhibiting binding of fibrinogen to GPHb/IIIa in a warm-blooded animal requiring such treatment which comprises administering an effective amount of the (-)-(3R) compound, or a pharmaceutically-acceptable salt, ester, amide or solvate thereof, substantially free of the (+)-(3S) stereoisomer.
  • a method of inhibiting thrombotic events accompanying unstable angina in a warm-blooded animal requiring such treatment comprises administering an effective amount of the (-)-(3R) compound, or a pharmaceutically-acceptable salt, ester, amide or solvate thereof, substantially free of the (+)-(3S) stereoisomer.
  • a method of inhibiting platelet aggregation in a warm-blooded animal requiring such treatment while substantially reducing adverse effects associated with the administration of the (3-RS)- racemic mixture which comprises administering an effective amount of the (-)-(3R) compound, or a pharmaceutically-acceptable salt, ester, amide or solvate thereof, substantially free of the (+)-(3S) stereoisomer.
  • the (-)-(3R) compound of the invention will be administered for this purpose by an oral, rectal, topical, intravenous, subcutaneous, intramuscular or inhalation route, so that a dose in the range of from 0.01 to 50 mg/kg body weight will be given, depending upon the route of_administration, the age and sex of the patient, and the severity of the condition to be treated.
  • the (-)-(3R) compound of the invention will generally be used in the form of a pharmaceutical composition
  • a pharmaceutical composition comprising the (-)-(3R) compound, or a pharmaceutically- acceptable salt, ester, amide or solvate thereof, substantially free of the (+)-(3S) stereoisomer, in admixture with a pharmaceutically-acceptable diluent or carrier.
  • Such a composition is provided as a further feature of the invention and may be in a variety of dosage forms.
  • it may be in the form of tablets, capsules, solutions or suspensions for oral administration; in the form of cream or ointments or a transdermal (skin) patch for topical administration; in the form of a suppository for rectal administration; in the form of a sterile solution or suspension for administration by intravenous or intramuscular injection; in the form of an aerosol or a nebuliser solution or suspension, for administration by inhalation; and in the form of a powder, together with pharmaceutically-acceptable inert solid diluents such as lactose, for administration by insufflation.
  • inert solid diluents such as lactose
  • composition may comprise, for example, for 0.1 to 99.9% by weight of the (-)-(3R) compound of the invention.
  • compositions may be obtained by conventional procedures using pharmaceutically-acceptable diluents and carriers well known in the art.
  • Tablets and capsules for oral administration may conveniently be formed with an enteric coating, for example comprising cellulose acetate phthalate, to minimise contact of the (-)-(3R) compound of the invention with stomach acids.
  • the (-)-(3R) compound of the invention may be co-adminstered or co-formulated with one or more agents known to be of value in the diseases or conditions intended to be treated, for example a known platelet aggregation inhibitor (e.g. aspirin, a thromboxane antagonist or a thromboxane synthase inhibitor), hypolipidemic agent, anti-hypertensive agent, thrombolytic agent (such as streptokinase, urokinase, prourokinase, tissue plasminogen activator and derivatives thereof), beta-adrenergic blocker or a vasodilator may usefully also be present in a pharmaceutical composition of the invention for use in treating a heart or vascular disease or condition.
  • a known platelet aggregation inhibitor e.g. aspirin, a thromboxane antagonist or a thromboxane synthase inhibitor
  • hypolipidemic agent e.g. aspirin
  • the (-)-(3R) compound of the invention is also useful as a pharmacological tool in the development and standardisation of test systems for the evaluation of the effects of adhesion molecules in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • the (-)-(3R) compound of the invention may also be used because of its platelet aggregation inhibitory properties in helping to store blood and to maintain the viability of blood and blood vessels in warm-blooded animals (or parts thereof) under-going artificial extracorporeal circulation, for example during limb or organ transplants.
  • the (-)-(3R) compound of the invention will generally be administered so that a steady state concentration in the range, for example, 0.1 to 10 mg per litre is achieved in the blood.
  • the aqueous solution was acidified by the addition of an aqueous citric acid solution and extracted with dichloromethane. The extracts were combined, washed with water and filtered through phase separating paper. The filtrate was evaporated to give 1-tert-butyl (3R)-3-methylsuccinate as an oil (12.9g).
  • p-Toluenesulphonyl chloride (13.2 g) was added portionwise to a stirred mixture of tert-butyl (3R)-4-hydroxy-3-methylbutyrate (11 g), triethylamine (21 ml) and dichloromethane (120 ml) and the mixture stirred for 20 hours. The mixture was washed in turn with water and dilute aqueous sodium carbonate solution. The organic solution was filtered through phase separating paper and evaporated to give tert-butyl (3R)-3-methyl-4- (p-toluenesulphonyloxy)butyrate as an oil (20 g).
  • Illustrative pharmaceutical dosage forms suitable for presenting the compound of the invention for therapeutic or prophylactic use include the following, which may be obtained by conventional procedures well known in the art:
  • Active ingredient 1.0 Lactose Ph. Eur. 93.25 Croscarmellose sodium 4.0 Maize starch paste 0.75 (5% w/v aqueous paste) Magnesium stearate 1.0
  • Active ingredient (acid addition salt) 1.0
  • the (-)-(3R) compound is less toxic than the (3RS)-racemic mixture.

Abstract

La présente invention se rapporte à l'acide (-)-(3R)-3-méthyl-4-{4-[4-(4-pyridyl)pipérazin-1-yl]phénoxy}butyrique, nouveau composé doté d'une activité optique, ainsi qu'à ses sels, esters, amides, ou solvates pharmaceutiquement acceptables. Cette invention concerne également des procédés de préparation de ce composé, des compositions pharmaceutiques contenant ce composé et l'utilisation de ce composé comme inhibiteur de l'adhésion cellulaire, et notamment de l'agrégation plaquettaire.
PCT/GB1996/001260 1995-06-01 1996-05-28 Acide (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazin-1-yl]phenoxy}butyrique inhibiteur d'adhesion cellulaire WO1996038416A1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE19680509T DE19680509T1 (de) 1995-06-01 1996-05-28 (-)-(3R)-3-Methyl-4-(4-(4-(4pyridyl)piperazin-1-yl)phenoxybuttersäure als Zellaadhäsionsinhibitor
CZ97269A CZ26997A3 (en) 1995-06-01 1996-05-28 Optically active (-)-(3r)-3.methyl-4-{4-£4-(4-pyridyl)piperazin-1-yl|phenoxy}butyric acid, derivatives thereof, process of their preparation and their use
AT0900596A AT406675B (de) 1995-06-01 1996-05-28 (-)-(3r)-3-methyl-4-(4-(4-(4-pyridyl) piperazin-1-yl)phenoxy)buttersäure als zellulärer adhäsionsinhibitor
JP8536281A JP2885941B2 (ja) 1995-06-01 1996-05-28 細胞付着抑制剤としての（−）−（３ｒ）−３−メチル−４−｛４−［４−（４−ピリジル）ピペラジン−１−イル］フェノキシ｝酪酸
BR9606409A BR9606409A (pt) 1995-06-01 1996-05-28 Composto opticamente ativo composição farmacêutica processos para inibir agregação de plaqueta em um animal de sangue quente ligação de fibrinogênio a gpiib/iia em um animal de sangue quente e eventos trombóticos que acompanham agnina instável em animal de sangue quente e uso do composto opticamante ativo
AU58272/96A AU710105B2 (en) 1995-06-01 1996-05-28 (-)-(3R0-3-methyl-4-(4-(4-(4-pyridyl)piperazin-1-yl)phenoxy) butyric acid as cellular adhesion inhibitor
MX9700379A MX9700379A (es) 1995-06-01 1996-05-28 Acido(-)-(3r)-3-metil-4-(4-(4-(4-piridil)piperazin-1-il)-fenoxi)butirico como inhibidor de la adhesion celular.
SK130-97A SK13097A3 (en) 1995-06-01 1996-05-28 Optically active (-)-(3r)-3-methyl-4-{4-£4-(4-pyridyl)piperazin- -1-yl|phenoxy} butyric acid and its derivatives, preparation method thereof and their use
EP96919906A EP0796247A1 (fr) 1995-06-01 1996-05-28 Acide (-)-(3r)-3-methyl-4-(4-(4-(4-pyridyl)piperazin-1-yl]phenoxy butyrique inhibiteur d'adhesion cellulaire
KR1019970700532A KR100245957B1 (ko) 1995-06-01 1996-05-28 (-)-(3r)-3-메틸-4-(4-(4-(4-피리딜)피페라진-1-일)페녹시)부티르산 세포부착 저해제
NZ308597A NZ308597A (en) 1995-06-01 1996-05-28 (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazin-1-yl]phenoxy} butyric acid derivatives; medicaments; used as cellular adhesion inhibitor
GB9627127A GB2304340B (en) 1995-06-01 1996-05-28 (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazin-1-yl]phenoxy} butyric acid as cellular adhesion inhibitor
LU90008A LU90008B1 (fr) 1995-06-01 1997-01-22 Acide(-)-(3R)-3-methyl-4-(4-(4-(4-pyridyl)piperazin-1-yl)-phenoxy)butyrique a titre d'inhibiteur de l'adhésion cellulaire
SE9700203A SE510812C2 (sv) 1995-06-01 1997-01-24 (-)-(3R)-3-metyl-4-(4-(4-(4-pyridyl)piperazin-1- yl)fenoxi)smörsyra som cellulär adhesionsinhibitor
DK010697A DK10697A (da) 1995-06-01 1997-01-30 (-)-(3R)-3-methyl-4-(4-(4-(4-pyridyl)Piperazinl-yl)phenoxy)smørsyre som cellulær adhæsionsinhibitor.
FI970393A FI970393A (fi) 1995-06-01 1997-01-30 (-)-(3R)-3-metyyli-4-(4-(4-(4-pyridyyli)piperatsin-1-yyli)fenoksi)voihappo soluadheesioinhibiittoreina
NO970437A NO307460B1 (no) 1995-06-01 1997-01-31 Optiske aktive forbindelser, fremgangsmõte for fremstilling derav, farmasøytisk blanding og anvendelse derav

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/457,538 1995-06-01
US08/457,538 US5652242A (en) 1993-03-29 1995-06-01 Heterocyclic derivatives
GBGB9518188.9A GB9518188D0 (en) 1995-09-07 1995-09-07 Optically active derivative
GB9518188.9 1995-09-07

Publications (1)

Publication Number Publication Date
WO1996038416A1 true WO1996038416A1 (fr) 1996-12-05

Family

ID=26307696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001260 WO1996038416A1 (fr) 1995-06-01 1996-05-28 Acide (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazin-1-yl]phenoxy}butyrique inhibiteur d'adhesion cellulaire

Country Status (31)

Country Link
EP (1) EP0796247A1 (fr)
JP (1) JP2885941B2 (fr)
KR (1) KR100245957B1 (fr)
AT (1) AT406675B (fr)
AU (1) AU710105B2 (fr)
BE (1) BE1009520A5 (fr)
BR (1) BR9606409A (fr)
CA (1) CA2194397A1 (fr)
CH (1) CH691808A5 (fr)
CZ (1) CZ26997A3 (fr)
DE (1) DE19680509T1 (fr)
DK (1) DK10697A (fr)
ES (1) ES2137886B1 (fr)
FI (1) FI970393A (fr)
GB (1) GB2304340B (fr)
GR (1) GR1002702B (fr)
HU (1) HUP9700274A3 (fr)
IE (1) IE960405A1 (fr)
IL (1) IL118477A0 (fr)
IT (1) IT1290839B1 (fr)
LU (1) LU90008B1 (fr)
MC (1) MC2418A1 (fr)
MX (1) MX9700379A (fr)
NL (1) NL1003243C2 (fr)
NO (1) NO307460B1 (fr)
NZ (1) NZ308597A (fr)
PL (1) PL318440A1 (fr)
SE (1) SE510812C2 (fr)
SK (1) SK13097A3 (fr)
TR (1) TR199700020T1 (fr)
WO (1) WO1996038416A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022834A1 (fr) * 1993-03-29 1994-10-13 Zeneca Limited Derives heterocycliques utilises comme inhibiteurs d'agregation plaquettaire
WO1994022835A2 (fr) * 1993-03-29 1994-10-13 Zeneca Limited Composes heterocycliques en tant qu'inhibiteurs de l'agregation plaquettaire

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100158A3 (fr) * 1982-07-28 1985-03-27 The Upjohn Company Hétéroalkysylalkanoles 3-pyridinyliques, leurs acides alkanoiques et leurs esters
GB8609630D0 (en) * 1986-04-19 1986-05-21 Pfizer Ltd Anti-arrhythmia agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022834A1 (fr) * 1993-03-29 1994-10-13 Zeneca Limited Derives heterocycliques utilises comme inhibiteurs d'agregation plaquettaire
WO1994022835A2 (fr) * 1993-03-29 1994-10-13 Zeneca Limited Composes heterocycliques en tant qu'inhibiteurs de l'agregation plaquettaire

Also Published As

Publication number Publication date
NO307460B1 (no) 2000-04-10
SK13097A3 (en) 1997-08-06
AU710105B2 (en) 1999-09-16
SE9700203D0 (sv) 1997-01-24
IT1290839B1 (it) 1998-12-14
JPH09512836A (ja) 1997-12-22
PL318440A1 (en) 1997-06-09
CA2194397A1 (fr) 1996-12-05
NO970437L (no) 1997-02-20
GB2304340B (en) 1998-07-29
NO970437D0 (no) 1997-01-31
AT406675B (de) 2000-07-25
NZ308597A (en) 1998-11-25
ES2137886A1 (es) 1999-12-16
JP2885941B2 (ja) 1999-04-26
ITMI961113A0 (it) 1996-05-31
EP0796247A1 (fr) 1997-09-24
GB2304340A (en) 1997-03-19
HUP9700274A3 (en) 2000-02-28
ES2137886B1 (es) 2000-08-16
ATA900596A (de) 1999-12-15
HU9700274D0 (en) 1997-04-28
NL1003243C2 (nl) 1996-12-04
GB9627127D0 (en) 1997-02-19
FI970393A0 (fi) 1997-01-30
GR1002702B (el) 1997-05-22
ITMI961113A1 (it) 1997-12-01
TR199700020T1 (tr) 1997-04-22
DK10697A (da) 1997-04-01
BR9606409A (pt) 1997-09-30
SE510812C2 (sv) 1999-06-28
LU90008B1 (fr) 1997-04-16
SE9700203L (sv) 1997-01-24
IL118477A0 (en) 1996-09-12
FI970393A (fi) 1997-01-30
AU5827296A (en) 1996-12-18
CH691808A5 (de) 2001-10-31
CZ26997A3 (en) 1997-08-13
KR100245957B1 (ko) 2000-04-01
IE960405A1 (en) 1996-12-11
HUP9700274A2 (hu) 1999-06-28
BE1009520A5 (fr) 1997-04-01
DE19680509T1 (de) 1997-12-04
MX9700379A (es) 1997-04-30
KR970704689A (ko) 1997-09-06
MC2418A1 (fr) 1997-05-23

Similar Documents

Publication Publication Date Title
JP2020516666A (ja) アポトーシス誘発剤
US5935963A (en) Piperazinones, their production and use
JP2003514808A (ja) 抗炎症剤としての尿素誘導体
CN114478485B (zh) 作为vanin抑制剂的杂芳族化合物
EP0950658A1 (fr) Dérivé dihydrochloride d'un 2-Piperazinone-1-acetic acid utile pour l'inhibition de l'aggrégation de plaquettes
AU758246B2 (en) N,N-substituted cyclic amine derivatives
EP1124824B1 (fr) Derives de chromenone et de chromanone utilises comme inhibiteurs d'integrine
KR100300566B1 (ko) 피리미디논유도체와그의제조방법및용도
IE55263B1 (en) Thiomethylpyridine derivatives,process for the production thereof and medicaments containing them
AU710105B2 (en) (-)-(3R0-3-methyl-4-(4-(4-(4-pyridyl)piperazin-1-yl)phenoxy) butyric acid as cellular adhesion inhibitor
CN101522610A (zh) 氨基醇的硝酸酯
JPH037280A (ja) 新規ベンゾチオピラニルアミン
JP3786983B2 (ja) ピロリジノン誘導体
EP2757103A1 (fr) Dérivé de l'acide pyrrolidin-3-ylacétique
AU672984B2 (en) Novel oxazolidines
KR20010075546A (ko) 트롬빈 억제제로서의 벤즈아미드 유도체
JP2837318B2 (ja) アンジオテンシンｉｉ拮抗性ピリジン誘導体
CZ340697A3 (cs) Fenylamidinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
MXPA02006904A (es) Fenilamidinas sustituidas, medicinas conteniendo estos compuestos y procedimientos para su preparacion.
RU2339634C2 (ru) Кристаллическая форма
FR2734818A1 (fr) Acide (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazine-1-yl- phenoxy}-butyrique, procede pour sa preparation et composition pharmaceutique le contenant
US20220306637A1 (en) Imidazopyrazine Derivatives and the Use Thereof as Medicament
US5675011A (en) Process for producing pyrrolidine derivative and salt thereof
JPH06256331A (ja) 血管新生阻害剤
CA2022115A1 (fr) Composes d'imidazole et leur utilisation comme inhibiteurs de la transglutaminase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96190594.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

WWE Wipo information: entry into national phase

Ref document number: 2194397

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 308597

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 97/00020

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/000379

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1996 9005

Country of ref document: AT

Date of ref document: 19961205

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 19969005

Country of ref document: AT

WWE Wipo information: entry into national phase

Ref document number: 97002034

Country of ref document: SE

WWP Wipo information: published in national office

Ref document number: 97002034

Country of ref document: SE

WWE Wipo information: entry into national phase

Ref document number: 1019970700532

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV1997-269

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 9750006

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P009750006

Country of ref document: ES

Ref document number: 13097

Country of ref document: SK

Ref document number: 970393

Country of ref document: FI

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996919906

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1997-269

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019970700532

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996919906

Country of ref document: EP

RET De translation (de og part 6b)

Ref document number: 19680509

Country of ref document: DE

Date of ref document: 19971204

WWE Wipo information: entry into national phase

Ref document number: 19680509

Country of ref document: DE

WWG Wipo information: grant in national office

Ref document number: 1019970700532

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 9750006

Country of ref document: ES

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 1996919906

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 9750006

Country of ref document: ES

Kind code of ref document: A

WWR Wipo information: refused in national office

Ref document number: PV1997-269

Country of ref document: CZ

WWX Former pct application expired in national office

Ref document number: 9750006

Country of ref document: ES

Kind code of ref document: A